Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Durez

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Arthritis Care & Research|October 17, 2015
Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical TrialPaul Emery, Roy M Fleischmann, Ingrid Strusberg, et al.
Arthritis Research & Therapy|September 20, 2017
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentMichael Schiff, Tsutomu Takeuchi, Roy Fleischmann, et al.
Annals of the Rheumatic Diseases|December 16, 2006
Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritisFederico Díaz-González, Rieke H E Alten, William G Bensen, et al.
Arthritis Research & Therapy|October 7, 2005
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatmentBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Arthritis and Rheumatism|March 15, 2011
The anti-CD20 antibody rituximab reduces the Th17 cell responseFrank L van de Veerdonk, Bernard Lauwerys, Renoud J Marijnissen, et al.
Arthritis and Rheumatism|August 1, 2009
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritisPaul Emery, Roy M Fleischmann, Larry W Moreland, et al.
Plos One|May 1, 2015
Heterogeneity of synovial molecular patterns in patients with arthritisBernard R Lauwerys, Daniel Hernández-Lobato, Pierre Gramme, et al.
The Journal of Rheumatology|April 17, 2018
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb TrialMark C Genovese, César Pacheco-Tena, Arturo Covarrubias, et al.
Rheumatology (Oxford, England)|April 27, 2016
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumabNathan Vastesaeger, Abraham Garcia Kutzbach, Howard Amital, et al.
Clinical and Experimental Rheumatology|November 30, 2020
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational toolsGerd-Rüdiger Burmester, José María Álvaro-Gracia, Neil Betteridge, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Arthritis Care & Research|October 17, 2015
Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical TrialPaul Emery, Roy M Fleischmann, Ingrid Strusberg, et al.
Arthritis Research & Therapy|September 20, 2017
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentMichael Schiff, Tsutomu Takeuchi, Roy Fleischmann, et al.
Annals of the Rheumatic Diseases|December 16, 2006
Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritisFederico Díaz-González, Rieke H E Alten, William G Bensen, et al.
Arthritis Research & Therapy|October 7, 2005
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatmentBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Arthritis and Rheumatism|March 15, 2011
The anti-CD20 antibody rituximab reduces the Th17 cell responseFrank L van de Veerdonk, Bernard Lauwerys, Renoud J Marijnissen, et al.
Arthritis and Rheumatism|August 1, 2009
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritisPaul Emery, Roy M Fleischmann, Larry W Moreland, et al.
Plos One|May 1, 2015
Heterogeneity of synovial molecular patterns in patients with arthritisBernard R Lauwerys, Daniel Hernández-Lobato, Pierre Gramme, et al.
The Journal of Rheumatology|April 17, 2018
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb TrialMark C Genovese, César Pacheco-Tena, Arturo Covarrubias, et al.
Rheumatology (Oxford, England)|April 27, 2016
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumabNathan Vastesaeger, Abraham Garcia Kutzbach, Howard Amital, et al.
Clinical and Experimental Rheumatology|November 30, 2020
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational toolsGerd-Rüdiger Burmester, José María Álvaro-Gracia, Neil Betteridge, et al.
Pageof 12